AbbVie, Besins must pay $448 million in FTC AndroGel case, judge rules
AbbVie and Besins Healthcare violated antitrust law by filing sham patent litigation to delay the availability of generic AndroGel, a Philadelphia federal judge ruled Friday, ordering the companies to pay $448...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: